Do analysts prefer MRAI or BDSX?

Biodesix has a consensus price target of $35.00, indicating a potential upside of 26.26%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has preferable valuation & earnings, MRAI or BDSX?

Marpai has higher earnings, but lower revenue than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 2.65 -$28.75M -$0.77 N/A Biodesix $88.50M 3.30 -$35.26M -$3.17 N/A

Is MRAI or BDSX more profitable?

Biodesix has a net margin of -26.97% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Biodesix -26.97% -788.19% -30.33%

Do analysts prefer MRAI or INFU?

InfuSystem has a consensus price target of $17.50, indicating a potential upside of 32.98%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InfuSystem 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation & earnings, MRAI or INFU?

InfuSystem has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 2.65 -$28.75M -$0.77 N/A InfuSystem $143.34M 1.85 $870K $0.41 32.10

Is MRAI or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to Marpai's net margin of -85.70%. InfuSystem's return on equity of 2.78% beat Marpai's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% InfuSystem 1.12% 2.78% 1.41%

Do analysts prefer MRAI or XGN?

Exagen has a consensus target price of $9.63, indicating a potential upside of 17.81%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89

Which has higher valuation and earnings, MRAI or XGN?

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 2.65 -$28.75M -$0.77 N/A Exagen $66.57M 2.97 -$19.95M -$0.81 N/A

Is MRAI or XGN more profitable?

Exagen has a net margin of -26.61% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Exagen -26.61% -104.46% -28.93%

Do analysts recommend AIRS or MRAI?

AirSculpt Technologies presently has a consensus price target of $4.50, suggesting a potential upside of 154.24%. Given AirSculpt Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe AirSculpt Technologies is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AirSculpt Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate MRAI or LFMD?

LifeMD has a consensus target price of $7.57, suggesting a potential upside of 176.33%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has higher earnings and valuation, MRAI or LFMD?

LifeMD has higher revenue and earnings than Marpai. LifeMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 2.65 -$28.75M -$0.77 N/A LifeMD $194.05M 0.68 $14.35M -$0.05 N/A

Is MRAI or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% LifeMD 0.10% -168.23% -31.27%

Marpai (MRAI) Competitors

$3.43 +0.13 (+4.07%)

As of 02:49 PM Eastern

Compare

MRAI vs. BDSX, INFU, XGN, AIRS, and LFMD

Should you buy Marpai stock or one of its competitors? Marpai's main competitors and comparable companies include Biodesix (BDSX), InfuSystem (INFU), Exagen (XGN), AirSculpt Technologies (AIRS), and LifeMD (LFMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Marpai compare to Biodesix?

Marpai (NASDAQ:MRAI) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

In the previous week, Biodesix had 6 more articles in the media than Marpai. MarketBeat recorded 6 mentions for Biodesix and 0 mentions for Marpai. Biodesix's average media sentiment score of 0.38 beat Marpai's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
Biodesix	Neutral

Marpai has a beta of 4.73, indicating that its share price is 373% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Biodesix has a consensus price target of $35.00, indicating a potential upside of 26.26%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Marpai has higher earnings, but lower revenue than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	2.65	-$28.75M	-$0.77	N/A
Biodesix	$88.50M	3.30	-$35.26M	-$3.17	N/A

49.8% of Marpai shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Biodesix has a net margin of -26.97% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Biodesix	-26.97%	-788.19%	-30.33%

Summary

Biodesix beats Marpai on 10 of the 17 factors compared between the two stocks.

How does Marpai compare to InfuSystem?

Marpai (NASDAQ:MRAI) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

InfuSystem has a net margin of 1.12% compared to Marpai's net margin of -85.70%. InfuSystem's return on equity of 2.78% beat Marpai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
InfuSystem	1.12%	2.78%	1.41%

In the previous week, InfuSystem's average media sentiment score of 0.80 beat Marpai's score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
InfuSystem	Positive

InfuSystem has a consensus price target of $17.50, indicating a potential upside of 32.98%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

InfuSystem has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	2.65	-$28.75M	-$0.77	N/A
InfuSystem	$143.34M	1.85	$870K	$0.41	32.10

49.8% of Marpai shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Marpai has a beta of 4.73, indicating that its share price is 373% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Summary

InfuSystem beats Marpai on 12 of the 15 factors compared between the two stocks.

How does Marpai compare to Exagen?

Marpai (NASDAQ:MRAI) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Exagen has a net margin of -26.61% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Exagen	-26.61%	-104.46%	-28.93%

Marpai has a beta of 4.73, indicating that its share price is 373% more volatile than the broader market. Comparatively, Exagen has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market.

In the previous week, Exagen had 1 more articles in the media than Marpai. MarketBeat recorded 1 mentions for Exagen and 0 mentions for Marpai. Marpai's average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
Exagen	Neutral

49.8% of Marpai shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	2.65	-$28.75M	-$0.77	N/A
Exagen	$66.57M	2.97	-$19.95M	-$0.81	N/A

Exagen has a consensus target price of $9.63, indicating a potential upside of 17.81%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Exagen beats Marpai on 11 of the 16 factors compared between the two stocks.

How does Marpai compare to AirSculpt Technologies?

AirSculpt Technologies (NASDAQ:AIRS) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

AirSculpt Technologies has higher revenue and earnings than Marpai. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82M	0.84	-$11.67M	-$0.18	N/A
Marpai	$34.87M	2.65	-$28.75M	-$0.77	N/A

AirSculpt Technologies presently has a consensus price target of $4.50, suggesting a potential upside of 154.24%. Given AirSculpt Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe AirSculpt Technologies is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

91.5% of AirSculpt Technologies shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 44.6% of AirSculpt Technologies shares are owned by insiders. Comparatively, 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AirSculpt Technologies has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Marpai has a beta of 4.73, indicating that its stock price is 373% more volatile than the broader market.

In the previous week, AirSculpt Technologies had 3 more articles in the media than Marpai. MarketBeat recorded 3 mentions for AirSculpt Technologies and 0 mentions for Marpai. AirSculpt Technologies' average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
AirSculpt Technologies	Neutral
Marpai	Neutral

AirSculpt Technologies has a net margin of -7.79% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat AirSculpt Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.79%	-5.83%	-2.88%
Marpai	-85.70%	N/A	-100.23%

Summary

AirSculpt Technologies beats Marpai on 9 of the 14 factors compared between the two stocks.

How does Marpai compare to LifeMD?

Marpai (NASDAQ:MRAI) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Marpai's average media sentiment score of 0.00 equaled LifeMD'saverage media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
LifeMD	Neutral

LifeMD has a net margin of 0.10% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
LifeMD	0.10%	-168.23%	-31.27%

LifeMD has higher revenue and earnings than Marpai. LifeMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	2.65	-$28.75M	-$0.77	N/A
LifeMD	$194.05M	0.68	$14.35M	-$0.05	N/A

LifeMD has a consensus target price of $7.57, suggesting a potential upside of 176.33%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

49.8% of Marpai shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Marpai has a beta of 4.73, meaning that its share price is 373% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market.

Summary

LifeMD beats Marpai on 8 of the 14 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$92.34M	$9.56B	$7.14B	$13.10B
Dividend Yield	N/A	2.61%	2.54%	16.77%
P/E Ratio	-1.30	34.09	273.67	26.04
Price / Sales	2.65	4.85	602.53	86.50
Price / Cash	N/A	120.59	77.60	51.75
Price / Book	-1.99	5.15	10.92	6.30
Net Income	-$28.75M	$315.68M	$3.50B	$361.43M
7 Day Performance	8.54%	-2.87%	-2.11%	-1.67%
1 Month Performance	38.59%	-2.92%	-6.34%	-3.94%
1 Year Performance	138.19%	8.65%	8.81%	2.77%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$3.43 +4.1%	N/A	+140.6%	$92.34M	$34.87M	N/A	150
BDSX Biodesix	4.1781 of 5 stars	$29.62 +5.2%	$31.33 +5.8%	+256.3%	$311.41M	$102.94M	N/A	334	News Coverage
INFU InfuSystem	3.9061 of 5 stars	$12.69 -3.2%	$17.50 +38.0%	+24.8%	$256.01M	$143.34M	211.45	473
XGN Exagen	2.8735 of 5 stars	$8.53 -0.2%	$9.63 +12.8%	-28.1%	$207.95M	$71.12M	N/A	220
AIRS AirSculpt Technologies	1.2098 of 5 stars	$2.11 -16.6%	$4.50 +113.4%	-79.1%	$152.28M	$151.82M	N/A	363	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors